Improvements in lung function with umeclidinium/vilanterol versus fluticasone propionate/salmeterol in patients with moderate-to-severe COPD and infrequent exacerbations

On behalf of my co-authors, I would like to thank Dr Banerji and Dr Patalano for their interest in our recently published article demonstrating the benefits of once-daily umeclidinium/vilanterol 62.5/25 mcg (UMEC/VI) versus twice-daily fluticasone propionate/salmeterol 250/50 mcg (FP/SAL) in patients with moderate-to-severe COPD. Dr Banerji and Dr Patalano quite rightly highlight the similarities of our findings and those of the ILLUMINATE and LANTERN studies [1, 2], which further support the benefits of combined long-acting muscarinic antagonist (LAMA)/long-acting β2-agonist (LABA) treatments in COPD.
Source: Respiratory Medicine CME - Category: Respiratory Medicine Authors: Source Type: research